Kolexia
Cazaubiel Titouan Oncologie hémato.
Cazaubiel Titouan
Oncologie hémato.
Hôpital Haut-lévêque
Pessac, France
47 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Myélome multiple Aberrations des chromosomes Leucémies Leucémie à plasmocytes Récidive tumorale locale Leucémie aigüe myéloïde Leucémie-lymphome lymphoblastique à précurseurs B Leucémie-lymphome lymphoblastique à précurseurs B et T Chromosome Philadelphie

Collaborateurs

Voir plus
Hulin Cyrille
Hulin Cyrille
Hôpital Haut-lévêque, Pessac, France
Perrot Aurore
Perrot Aurore
Oncopole Toulouse, Toulouse, France
Laboure Gaelle
Laboure Gaelle
Centre Hospitalier Libourne, Libourne, France
Adiko Didier
Adiko Didier
Centre Hospitalier Libourne, Libourne, France

Industries

Voir plus
Janssen
14 collaboration(s)
Dernière en 2023
Takeda Pharmaceutical
7 collaboration(s)
Dernière en 2023
Amgen
6 collaboration(s)
Dernière en 2023
Sanofi
5 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study on the behalf of G2I and IFM.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases   01 mars 2024
Biallelic Deletion of 1p32 Defines Ultra-High-Risk Myeloma, but ...
Medscape   18 janvier 2024
Biallelic Deletion of 1p32 Defines Ultra-High-Risk Myeloma, but ...
Medscape   27 décembre 2023
Biallelic Deletion of 1p32 Defines Ultra-High-Risk Myeloma, but ...
Medscape   18 décembre 2023
Biallelic Deletion of 1p32 Defines Ultra-High-Risk Myeloma, but ...
Medscape   03 décembre 2023
Cumulative Incidence and Characteristics of Infections Requiring Treatment, Delay in Treatment Administration or Hospitalisation in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti BCMA or Anti GPRC5D Bispecific Antibodies
65th ASH Annual Meeting Abstracts   02 novembre 2023
Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions.
Blood cancer journal   26 octobre 2023
TEC-CARE: Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients: a Collaborative Janssen - IFM Study IFM 2023-01: TEC-CARE
Essai Clinique (Janssen)   28 septembre 2023
Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma.
Haematologica   01 mai 2023
Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.
Blood   21 mars 2023